Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donika Plyku

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 28, 2026
Utility of Preclinical Dosimetry for First-in-Human Studies with PET Drugs Labeled with Common Radionuclides: A Systematic Review of Radiation Dose EstimatesHayoung Koo, Donika Plyku, Libero Marzella
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 10, 2025
Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET RadiopharmaceuticalsDonika Plyku, Hayoung Koo, Luke Park, et al.
Annals of Nuclear Medicine|February 4, 2022
I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment responseDonika Plyku, Robert F Hobbs, Di Wu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2017
Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in <sup>124</sup>I PET/CT-Based Dosimetry for <sup>131</sup>I Therapy of Metastatic Differentiated Thyroid CancerDonika Plyku, Robert F Hobbs, Kevin Huang, et al.
Nuclear Medicine Communications|December 16, 2020
The spectrum of 124I uptake in the lacrimal gland and nasolacrimal sac/duct on PET/CT imagingDi Wu, Donika Plyku, Kanchan Kulkarni, et al.
Physics in Medicine and Biology|March 2, 2016
A risk index for pediatric patients undergoing diagnostic imaging with (99m)Tc-dimercaptosuccinic acid that accounts for body habitusShannon E O'Reilly, Donika Plyku, George Sgouros, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 13, 2015
Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional DosimetryDonika Plyku, David M Loeb, Andrew R Prideaux, et al.
Clinical Nuclear Medicine|January 25, 2021
Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid CancerDi Wu, Donika Plyku, Kanchan Kulkarni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 21, 2018
Combined model-based and patient-specific dosimetry for <sup>18</sup>F-DCFPyL, a PSMA-targeted PET agentDonika Plyku, Esther Mena, Steven P Rowe, et al.
EJNMMI Research|March 19, 2016
Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-oldsKitiwat Khamwan, Donika Plyku, Shannon E O'Reilly, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 28, 2026
Utility of Preclinical Dosimetry for First-in-Human Studies with PET Drugs Labeled with Common Radionuclides: A Systematic Review of Radiation Dose EstimatesHayoung Koo, Donika Plyku, Libero Marzella
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 10, 2025
Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET RadiopharmaceuticalsDonika Plyku, Hayoung Koo, Luke Park, et al.
Annals of Nuclear Medicine|February 4, 2022
I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment responseDonika Plyku, Robert F Hobbs, Di Wu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 21, 2017
Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in <sup>124</sup>I PET/CT-Based Dosimetry for <sup>131</sup>I Therapy of Metastatic Differentiated Thyroid CancerDonika Plyku, Robert F Hobbs, Kevin Huang, et al.
Nuclear Medicine Communications|December 16, 2020
The spectrum of 124I uptake in the lacrimal gland and nasolacrimal sac/duct on PET/CT imagingDi Wu, Donika Plyku, Kanchan Kulkarni, et al.
Physics in Medicine and Biology|March 2, 2016
A risk index for pediatric patients undergoing diagnostic imaging with (99m)Tc-dimercaptosuccinic acid that accounts for body habitusShannon E O'Reilly, Donika Plyku, George Sgouros, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 13, 2015
Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional DosimetryDonika Plyku, David M Loeb, Andrew R Prideaux, et al.
Clinical Nuclear Medicine|January 25, 2021
Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid CancerDi Wu, Donika Plyku, Kanchan Kulkarni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 21, 2018
Combined model-based and patient-specific dosimetry for <sup>18</sup>F-DCFPyL, a PSMA-targeted PET agentDonika Plyku, Esther Mena, Steven P Rowe, et al.
EJNMMI Research|March 19, 2016
Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-oldsKitiwat Khamwan, Donika Plyku, Shannon E O'Reilly, et al.
Pageof 3